India, April 18 -- Certara(R), the global leader in model-informed drug development, regulatory science, real-world evidence and market access services has announced four senior executive appointments in its Simcyp division. Simcyp is the leading provider of innovative mechanistic modeling technologies used to inform drug development, including physiologically-based pharmacokinetic (PBPK), quantitative systems pharmacology (QSP) and quantitative systems toxicology and safety (QSTS) approaches.

For example, the Simcyp Simulator has been used to inform 50 novel drug applications, including more than 200 label claims made without the need for clinical trials.

Rob Aspbury,PhD, joins Simcyp as Chief Operating Officer; Frederic Yves Bois, Pha...